Table 2. Clinicopathological data of analyzed samples.

Biopsy Samples	Diagnosis	Number of Neoplastic Cellsa	Tumor cell enrichment
N=14
	14 Adenocarcinoma	848-42,504 (median: 11,828)	15-80% (median: 60.0%)
	9 Primary
	5Metastasis (LN 3, Bone 2)
Cytology Samples	Diagnosis	Number of Neoplastic Cellsb	Tumor cell enrichment
N=66		190-730,000 (median: 11,200)	5-80% (median: 42.5%)
	38 Adenocarcinoma	952-228,150 (median: 3,956)	10-80% (median: 32.5%)
	24Primary
	12Metastasis (LN 10, Pleura 2)
	2 Pleural Effusion
	28 NSCLC	190-730,000 (median: 18,000)	5-80% (median: 50.0%)
	23Primary
	5 Metastasis (LN 5)
Total Samples	Diagnosis	Number of Neoplastic Cellsa,b	Tumor cell enrichment
N=80		190-730,000 (median: 17,400)	5-80% (median: 50.0%)
	52 Adenocarcinoma	848-228,150 (median: 5,000)	10-80% (median: 45.0%)
	33 Primary
	17Metastasis (LN 13, Pleura 2, Bone 2)
	2 Pleural Effusion
	28 NSCLC	190-730,000 (median: 18,000)	5-80% (median: 50.0%)
	23Primary
	5 Metastasis (LN 5)

^aNumber of neoplastic cells was evaluated in all 14 biopsy samples; ^bNumber of neoplastic cells was evaluated in 39 of 66 cytology samples; quantitative estimation of the proportion of neoplastic cells was performed on all 80 cases. LN, Lymph Node; NSCLC, Non Small Cell Lung Carcinoma.